Arvinas Inc.

ARVN

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 68,057Value: $807K

# Signal Note: Deerfield Initiates ARVN Position Deerfield's $807K entry into Arvinas signals confidence in the company's PROTAC platform, likely driven by upcoming catalysts around its lead candidate bavisant (ARV-471), a selective estrogen receptor degrader in Phase 2 for ER+/HER2- breast cancer competing against established endocrine therapies. The timing suggests positioning ahead of potential 2024-2025 clinical readouts or partnership developments, as PROTAC degrader validation remains a key de-risking milestone for the platform's commercial viability.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: